We're at the #OTS23 Meeting this week -- excited to share updates on our application of #AI to the discovery and development of #oligonucleotide and #RNA therapeutics.
Stop by to learn more at the following 4 posters.
oligotherapeutics.org/2023-a…
Découvrez ce nouveau travail étonnant du sponsor bronze de Vecteur @deepgenomics et du cofondateur de Vecteur, Brendan Frey. Comme indiqué ci-dessous, l'équipe a développé le premier modèle de base pour les thérapies ARN 👇
We are thrilled to share our manuscript ‘An RNA foundation model enables discovery of disease mechanisms and candidate therapeutics’ as a preprint! 🧵
biorxiv.org/content/10.1101/…
Check out this amazing new work from Vector Bronze Sponsor @deepgenomics & Vector co-founder Brendan Frey. As outlined below the team developed the first foundation model for RNA therapeutics 👇
We are thrilled to share our manuscript ‘An RNA foundation model enables discovery of disease mechanisms and candidate therapeutics’ as a preprint! 🧵
biorxiv.org/content/10.1101/…
We are thrilled to share our manuscript ‘An RNA foundation model enables discovery of disease mechanisms and candidate therapeutics’ as a preprint! 🧵
biorxiv.org/content/10.1101/…
15/16 Here it’s important to have accurate predictions to lower the number of drugs screened. We analyzed variants in ClinVar that are amenable to this approach.
16/16 We hope that our model BigRNA, and more RNA foundation models like it, will continue to transform the fields of disease variant interpretation and personalized therapeutics